 | Up a level |
Journal Article
Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Boehme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Hoehling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Mueller, H-W., Mueller, S. C., Ost, E., Rahbar, K., Reifenhaeuser, W., Schaefers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B. and Essler, M. (2018). Lutetium-177-PSMA radioligand therapy. Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and Cologne and the MDK Nordrhein. Urologe, 57 (6). S. 709 - 714. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Brandt, Maximilian Peter, Ruf, C., Dieckmann, K. P., Syring, I, Ruckes, C., Nestler, T., Schmelz, H. U., Dotzauer, R., Hiester, A., Albers, P., Nettersheim, D., Bolenz, C., Loosen, S. H., Heidenreich, A., Pfister, D., Haferkamp, A., Zengerling, F. and Paffenholz, P. (2022). Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer. World J. Urol., 40 (2). S. 327 - 335. NEW YORK: SPRINGER. ISSN 1433-8726
Carles, J., Alcaraz, A., Clarke, N. W., Conde, A., Heidenreich, A., Juarez, A., Maroto Rey, J. P., Puente, J., Hernandez-Medrano, I., Salcedo, I., Haddad, I., Munoz del Toro, J., Servan, A., Pissart, G., Casariego, J. and Fizazi, K. (2020). ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region). Ann. Oncol., 31. S. S549 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Chowdhury, S., Shore, N., Saad, F., Higano, C. S., Fizazi, K., Iversen, P., Miller, K., Heidenreich, A., Ueda, T., Kim, C. S., Phung, D., Krivoshik, A., Wang, F., Wu, K. and Tombal, B. (2016). Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Corcoran, N. M., Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2017). Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain. Asia-Pac. J. Clin. Oncol., 13. S. 57 - 58. HOBOKEN: WILEY. ISSN 1743-7563
Gillessen, S., Lauritsen, J., Sauve, N., Tryakin, A., Jiang, D. M., Huddart, R. A., Heng, D. Y. C., Terbuch, A., Winquist, E., Chovanec, M., Hentrich, M., Fankhauser, C. D., Shamash, J., Garcia Del Muro, X., Vaughn, D. J., Heidenreich, A., Jandari, A., Collette, L., Beyer, J. and Daugaard, K. G. (2022). Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database. Ann. Oncol., 33 (7). S. S777 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Grabbert, M., Huesch, T., Kretschmer, A., Kirschner-Hermanns, R., Anding, R., Rose, A., Friedl, A., Obaje, A., Heidenreich, A., Brehmer, B., Naumann, C. M., Queissert, F., Loertzer, H., Pfitzenmaier, J., Nyarangi-Dix, J., Kurosch, M., Olianas, R., Homberg, R., Abdunnur, R., Schweiger, J., Hofmann, T., Wotzka, C., Pottek, T., Huebner, W., Haferkamp, A. and Bauer, R. M. (2019). Comparison of adjustable male slings and artificial urinary sphincter in the treatment of male urinary incontinence: a retrospective analysis of patient selection and postoperative continence status. World J. Urol., 37 (7). S. 1415 - 1421. NEW YORK: SPRINGER. ISSN 1433-8726
Gschwend, J. E., Albers, P., Boegemann, M., Goebell, P., Heidenreich, A., Klier, J., Koenig, F., Machtens, S., Pantel, K. and Thomas, C. (2018). Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data. Urologe, 57 (1). S. 34 - 40. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Haidl, F., Heidenreich, A., Grabbert, M., Kohl, T., Pfister, D. and Heidegger, I. (2018). The importance of Imaging studies to monitor treatment with novel androgen receptor pathway Inhibitors in metastatic castration resistant prostate cancer. Oncol. Res. Treat., 41. S. 78 - 79. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A. (2019). Educational research in urology. Innovations for improving training. Urologe, 58 (2). S. 114 - 126. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Heidenreich, A. (2018). Limits of surgery in uro-oncology. Urologe, 57 (9). S. 1058 - 1069. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Heidenreich, A. (2018). Radical retroperitoneal Nephrectomy. Aktuelle Urol., 49 (3). S. 275 - 289. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8820
Heidenreich, A. and Boehmer, D. (2016). Multimodal therapy of locally advanced prostate cancer. Urologe, 55 (3). S. 333 - 345. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., Haidl, F., Paffenholz, P., Pape, Ch., Neumann, U. and Pfister, D. (2017). Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann. Oncol., 28 (2). S. 362 - 368. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heidenreich, A., O'Sullivan, J., Gillessen, S., Heinrich, D., Gratt, J., Levy, J., Miller, K., Nilson, S., Saad, F., Tucci, M., Wirth, M. and Carles, J. (2016). Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration resistant prostate cancer (mCRCP) patients treated in an international early access program (EAP). Oncol. Res. Treat., 39. S. 86 - 88. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., Paffenholz, P., Haidl, F. and Pfister, D. (2017). At what time surgical Removal of metastases is indicated for testicular Germ Cell Tumors and is there a scientific Basis for this? Urologe, 56 (5). S. 627 - 637. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Heidenreich, A., Paffenholz, P., Nestler, T. and Pfister, D. (2022). Nerve sparing retroperitoneal lymph node dissection for clinical stage IIA/B seminomas: A clinical phase II trial. Ann. Oncol., 33 (7). S. S777 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Heidenreich, A., Saad, F., Caries, J., Gillessen, S., Heinrich, D., Gratt, J., Miller, K., Nilsson, S., O'Sullivan, J., Tucci, M. and Wirth, M. (2016). Effects of concomitant medication and baseline parameters on overall survival and safety in German metastatic castration-resistant prostate cancer patient subset treated with Radium-223 dichloride within the international early access program (iEAP). Oncol. Res. Treat., 39. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., Salem, J., Paffenholz, P. and Pfister, D. (2019). Interdisciplinary education in urology: innovations for better training. Urologe, 58 (8). S. 870 - 877. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2016). Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heinrich, D., Gillessen, S., Heidenreich, A., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Procopio, G., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Saad, F. (2016). Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Herden, J., Heidenreich, A. and Weissbach, L. (2016). TNM-Classification of localized prostate cancer. The clinical T-category does not correspond to the required demands. Urologe, 55 (12). S. 1564 - 1573. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Hiester, A., Paffenholz, P., Albers, P., Heidenreich, A. and Pfister, D. . Importance of residual tumor resection and desperation surgery in advanced germ cell tumors. Onkologe. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Hohberg, M., Kobe, C., Taeger, P., Hammes, J., Schmidt, M., Dietlein, F., Wild, M., Heidenreich, A., Drzezga, A. and Dietlein, M. (2019). Combined Early and Late [Ga-68]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol. Imaging. Biol., 21 (3). S. 558 - 567. NEW YORK: SPRINGER. ISSN 1860-2002
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K-P., Fizazi, K., Fossa, S., Germa-Lluch, J. R., Giannatempo, P., Gietema, J. A., Gillessen, S., Haugnes, H. S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M. A. S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondrus, D., Papachristofilou, A., Powles, T., Sohaib, A., Stahl, O., Tandstad, T., Toner, G. and Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann. Oncol., 29 (8). S. 1658 - 1687. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Kauffmann, C. and Heidenreich, A. (2018). Inferior vena cava thrombus recurrence after radical nephrectomy in renal cell carcinoma. Oncol. Res. Treat., 41. S. 168 - 170. BASEL: KARGER. ISSN 2296-5262
Kauffmann, C., Heidenreich, A. and Pfister, D. (2018). Enucleation of renal Tumors with variable complexity: perioperative complications and renal function. Oncol. Res. Treat., 41. S. 169 - 170. BASEL: KARGER. ISSN 2296-5262
Lenssen, R., Schmitz, K., Griesel, C., Heidenreich, A., Schulz, J. B., Trautwein, C., Marx, N., Fitzner, C., Jaehde, U. and Eisert, A. (2018). Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial. BMC Geriatr., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-2318
Macherey, S., Kauffmann, C., Heidenreich, A., Doerr, F., Wahlers, T. and Hekmat, K. (2017). Pulmonary metastasectomy in renal cell carcinoma. Urologe, 56 (8). S. 1025 - 1031. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262
Miller, K., Heinrich, D., O'Sullivan, J. M., Carles, J., Wirth, M., Nilsson, S., Huang, L., Kalinovsky, J., Heidenreich, A. and Saad, F. (2018). Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. S. 287 - 288. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Necchi, A., Bandini, M., Ross, J. S., Zhu, Y., Ding-Wei, Y., Ornellas, A., Watkin, N., Ayres, B., Hakenberg, O., Heidenreich, A., Raggi, D., Giannatempo, P., Marandino, L., Chipollini, J., Azizi, M., Brouwer, O., Grass, D., Johnstone, P., Albersen, M. and Spiess, P. (2020). Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma. Ann. Oncol., 31. S. S557 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Necchi, A., Pond, G. R., Raggi, D., Ottenhof, S., Horenblas, S., Khoo, V., Hakenberg, O., Heidenreich, A., Eigl, B. J., Nappi, L., Matsumoto, K., Vaishampayan, U., Woods, M., Giannatempo, P., Geynisman, D., Preto, M., Xylinas, E., Milowsky, M. I., Di Lorenzo, G. and Sonpavde, G. (2016). Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Paffenholz, P., Angerer-Shpilenya, M., Kauffmann, C., Grabbert, M., Nestler, T., Petermann-Meyer, A., Pfister, D. and Heidenreich, A. (2018). Distress screening in patients with urogenital malignancies. Oncol. Res. Treat., 41. S. 77 - 79. BASEL: KARGER. ISSN 2296-5262
Paffenholz, P., Heidegger, I. M., Kuhr, K., Loosen, S. H., Pfister, D. and Heidenreich, A. (2018). Re: Non-Guideline-Concordant Treatment of Testicular Cancer is Associated with Reduced Relapse-Free Survival Editorial Comment. J. Urol., 200 (5). S. 946 - 947. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1527-3792
Paffenholz, P., Nestler, T., Kauffmann, C., Grabbert, M., Pfister, D. and Heidenreich, A. (2018). Non-guideline concordant treatment of testicular cancer is associated with a reduced relapse-free survival. Oncol. Res. Treat., 41. S. 77 - 78. BASEL: KARGER. ISSN 2296-5262
Paffenholz, P., Nestler, T., Maatoug, Y., von Brandenstein, M., Loosen, S., Fischer, N., Pfister, D. and Heidenreich, A. (2020). Teratomatous elements in orchiectomy specimens are associated with a reduced relapse-free survival in metastasized testicular germ cell tumors. Oncol. Res. Treat., 43 (SUPPL 4). S. 126 - 127. BASEL: KARGER. ISSN 2296-5262
Paffenholz, P., Nestler, T., Pfister, D. and Heidenreich, A. (2020). Using pre-orchiectomy tumor marker levels for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging. Oncol. Res. Treat., 43 (SUPPL 4). S. 127 - 128. BASEL: KARGER. ISSN 2296-5262
Paffenholz, P., Nestler, T., Seelemeyer, F., von Brandenstein, M., Koeditz, B., Pfister, D. and Heidenreich, A. (2022). Early relapse in seminoma is associated with reduced overall survival. Ann. Oncol., 33 (7). S. S778 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Paffenholz, P., Pfister, D. and Heidenreich, A. (2016). Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours. Urologe, 55 (5). S. 632 - 641. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Paffenholz, P., Salem, J., Pfister, D., Porres, D. and Heidenreich, A. (2016). Workshop for surgical skills in Cologne by GeSRU. Urologe, 55 (11). S. 1494 - 1497. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B. and Gillessen, S. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 31 (9). S. 1119 - 1135. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Peine, A., Paffenholz, P., Hellmich, M., Martin, L., Roderburg, C., Heidenreich, A., Marx, G., Trautwein, C., Luedde, T. and Loosen, S. H. . Perception of the COVID-19 Pandemic among Pneumology Professionals in Germany. Pneumologie. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
Pfister, D., Epplen, R., Porres-Knoblauch, D. and Heidenreich, A. (2011). Possibilities for surgical correction of an anastomotic stricture after radical prostatectomy. Urologe, 50 (11). S. 1392 - 1395. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Pfister, D., Kohl, T., Porres, D., Haidl, F., Zugor, V. and Heidenreich, A. (2018). 68-Ga-PSMA-PET in lymph node staging in PSA recurrent prostate cancer-does the Primary influence the result. Oncol. Res. Treat., 41. S. 101 - 102. BASEL: KARGER. ISSN 2296-5262
Porres, D., Pfister, D., Thissen, A., Kuru, T. H., Zugor, V., Buettner, R., Knuechel, R., Verburg, F. A. and Heidenreich, A. (2017). The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis., 20 (1). S. 85 - 93. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5608
Reimer, R. P., Zaytoun, H., Klein, K., Sonnabend, K., Lennartz, S., Zopfs, D., Heidenreich, A., Maintz, D. and Hokamp, N. Grosse (2023). Detection and size measurements of kidney stones on virtual non-contrast reconstructions derived from dual-layer computed tomography in an ex vivo phantom setup. Eur. Radiol., 33 (4). S. 2995 - 3004. NEW YORK: SPRINGER. ISSN 1432-1084
Rexer, H., Heidenreich, A. and Hammerer, P. (2021). Operative Study on the Extension of Lymphadenectomy in intermediate and high-risk Prostate Cancer Prospective randomized Study Comparing an extensive and a restricted pelvic Lymphadenectomy as Part of radical Prostatectomy (SEAL-2) - AP 77/13 of the AUO. Urologe, 60 (9). S. 1245 - 1247. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Saad, F., Heidenreich, A., Heinrich, D., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Gillessen, S. (2016). Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Salem, J., Borgmann, H., Bruendl, J., Lausenmeyer, E. -M., Lent, V., Schroeder, A. and Heidenreich, A. (2016). Residents Training in the Private Practice Conflicts between Circumstances, Willingness, and Reality. Urologe, 55 (8). S. 1062 - 1071. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Salem, J., Paffenholz, P., Akbarov, I., Grabbert, M., Herden, J., Kauffmann, C., Pfister, D., Porres, D., Thissen, A., Zugor, V. and Heidenreich, A. (2017). Successful Start of the 1st Cologne Operation Workshop of GESRU. Urologe, 56 (7). S. 930 - 933. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Schenk, A., Esser, T., Wallberg, H., Bloch, W., Herden, J., Heidenreich, A. and Zimmer, P. (2018). Influence of acute endurance exercise on epigenetic modification, effector function and tumor infiltration of natural killer cells - a study protocol. Oncol. Res. Treat., 41. S. 163 - 164. BASEL: KARGER. ISSN 2296-5262
Schmidt, M. C., Pfister, O., Kobe, C., Dietlein, M., Dietlein, M., Heidenreich, A. and Drzezga, A. (2017). Tc-99m-PSMA-guided intraoperative lymph node localization in recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S750 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Schostak, M., Koenig, F., Boegemann, M., Goebell, P., Hammerer, P., Machtens, S., Schwentner, C., Thomas, C., von Amsberg, G., von Rundstedt, F. -C. and Heidenreich, A. (2018). Advanced Prostate Cancer Consensus Conference 2017. Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts. Urologe, 57 (7). S. 813 - 821. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Seidel, C., Zschaebitz, S., Hentrich, M., Paffenholz, P., Heidenreich, A., Ochsenreither, S., Oing, C. and Bokemeyer, C. (2020). Peritoneal carcinosis in germ cell tumor patients - a German Testicular Cancer Study Group (GTCSG) registry study. Oncol. Res. Treat., 43 (SUPPL 4). S. 257 - 258. BASEL: KARGER. ISSN 2296-5262
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Stenzl, A., Feyerabend, S., Syndikus, I., Sarosiek, T., Kuebler, H., Heidenreich, A., Cathomas, R., Gruellich, C., Loriot, Y., Perez Gracia, S. L., Gillessen, S., Klinkhardt, U., Schroeder, A., Schoenborn-Kellenberger, O., Reus, V., Koch, S. D., Hong, H. S., Seibel, T., Fizazi, K. and Gnad-Vogt, U. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Struck, J. P., Siegel, F., Kramer, M. W., Tsaur, I., Heidenreich, A., Haferkamp, A., Merseburger, A. S., Salem, J. and Borgmann, H. (2018). Substantial utilization of Facebook, Twitter, YouTube, and Instagram in the prostate cancer community. World J. Urol., 36 (8). S. 1241 - 1247. NEW YORK: SPRINGER. ISSN 1433-8726
Taeger, P. A., Hammes, J., Hohberg, M., Wild, M., Schomaecker, K., Kobe, C., Pfister, D., Heidenreich, A., Dietlein, M., Schmidt, M. and Drzezga, A. (2018). Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castrationresistant prostate cancer (mCRPC). Eur. J. Nucl. Med. Mol. Imaging, 45. S. S126 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Tesfamariam, Y. M., Jakob, T., Macherey, S., Monsef, I, Heidenreich, A., Becker, I, Kuhr, K. and Skoetz, N. (2018). Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: A Cochrane review and network meta-analysis. Oncol. Res. Treat., 41. S. 326 - 327. BASEL: KARGER. ISSN 2296-5262
Thomas, C., Boegemann, M., Koenig, F., Machtens, S., Schostak, M., Steuber, T. and Heidenreich, A. (2016). Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen. Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel. Urologe, 55 (6). S. 772 - 783. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Zastrow, S., Saad, F., Heinrich, D., Gillessen, S., OSullivan, J., Carles, J., Miller, K., Huang, L., Van Tol, Seeger M., Nilsson, S. and Heidenreich, A. (2017). Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). Oncol. Res. Treat., 40. S. 94 - 95. BASEL: KARGER. ISSN 2296-5262
von Deimling, M., Rajwa, P., Tilki, D., Heidenreich, A., Pallauf, M., Bianchi, A., Yanagisawa, T., Kawada, T., Karakiewicz, P., I, Gontero, P., Pradere, B., Ploussard, G., Rink, M. and Shariat, S. F. (2022). The current role of precision surgery in oligometastatic prostate cancer. ESMO Open, 7 (6). AMSTERDAM: ELSEVIER. ISSN 2059-7029
von Zehmen, T., Eich, C., Fries, J., von Brandenstein, M., Pfister, D. and Heidenreich, A. (2020). Surgical treatment of intracaval tumor relapse after radical tumor nephrectomy in locally advanced renal cell carcinoma. Urologe, 59 (10). S. 1217 - 1225. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563